Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Deals

Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development

Fineline Cube Jul 6, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...

Company Deals

Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy

Fineline Cube Jul 6, 2023

Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with...

Company Deals

Brii Biosciences Expands Collaboration with VBI Vaccines on Hepatitis B Virus Therapies

Fineline Cube Jul 6, 2023

China-based Brii Biosciences Ltd (HKG: 2137) has announced an expanded license agreement with US firm...

Policy / Regulatory

NMPA Launches “Drug Standard Management Measures” to Enhance Drug Quality and Safety

Fineline Cube Jul 6, 2023

The National Medical Products Administration (NMPA) has released the “Drug Standard Management Measures,” a set...

Company Policy / Regulatory

China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities

Fineline Cube Jul 6, 2023

This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...

Company Legal / IP

Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy

Fineline Cube Jul 6, 2023

Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award...

Company

Moderna Inc. Plans USD 1 Billion Investment in Shanghai for mRNA Vaccine Production

Fineline Cube Jul 6, 2023

US-based mRNA specialist Moderna Inc. (NASDAQ: MRNA) has revealed further details of its entry into...

Company Drug

CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China

Fineline Cube Jul 6, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for...

Company Drug

AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment

Fineline Cube Jul 6, 2023

US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical...

Company Drug

Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment

Fineline Cube Jul 5, 2023

Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...

Policy / Regulatory

CDE Releases 72nd Batch of Generic Reference Preparations with New Specifications

Fineline Cube Jul 5, 2023

The Center for Drug Evaluation (CDE) has released the 72nd batch of chemical generic reference...

Company Drug

Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication

Fineline Cube Jul 5, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication...

Company Drug

Abbisko Therapeutics’ EGFR Inhibitor ABSK112 Clears FDA for Global Phase I NSCLC Study

Fineline Cube Jul 5, 2023

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...

Company Drug

Jacobio Pharma’s KRAS Inhibitor Glecirasib Advances to Pivotal Pancreatic Cancer Trial

Fineline Cube Jul 5, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that it has received the green light from...

Company Drug

InnoCare Pharma Initiates Clinical Trial for TYK2 Inhibitor ICP-488 in Psoriasis Patients

Fineline Cube Jul 5, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced a significant milestone in the clinical...

Company Medical Device

ZAP-X Gyroscopic Radiosurgery Platform Receives NMPA Approval for Brain Tumor Treatment

Fineline Cube Jul 5, 2023

US-based Zap Surgical Systems Inc. has announced that it has received market approval in China...

Company Drug

NMPA Approves Pitolisant for Narcolepsy-Related Excessive Daytime Drowsiness and Cataplexy

Fineline Cube Jul 5, 2023

The National Medical Products Administration (NMPA) has approved pitolisant as a treatment for excessive daytime...

Company Drug

Ascentage Pharma’s Olverembatinib Gets NMPA Greenlight for Phase III Study in Ph+ ALL

Fineline Cube Jul 5, 2023

China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the National...

Company Drug

Amoytop Biotech’s Pegfilgrastim (Y Shape) Approved for Marketing by NMPA

Fineline Cube Jul 5, 2023

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has received marketing approval from the National Medical...

Company Deals

Jacobio Pharma Retakes Global Rights to SHP2 Inhibitors After Terminating AbbVie Agreement

Fineline Cube Jul 5, 2023

China-based Jacobio Pharma (HKG: 1167) has announced the cancellation of a licensing agreement with US...

Posts pagination

1 … 552 553 554 … 711

Recent updates

  • Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
  • WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.